ResultsIQ

ResultsIQ › Latest results › Neuland Laboratories Limited

Neuland Laboratories Limited Q2 FY27 results deck summary

NSE: NEULANDLAB · BSE: 524558

Results deck of 3 Nov 2026, summarised by AI from the filing.

Q2 FY27 total income fell 11.4% YoY to ₹457.2 cr and PAT to ₹51.1 cr, but management keeps FY27 growth expectations intact.

Key takeaways

  1. Q2 profit PAT fell to ₹51.1 cr from ₹96.5 cr in Q2FY26, with total income down 11.4% YoY to ₹457.2 cr.
  2. FY27 outlook Management expects growth expectations to remain intact for FY27 and the following year, with commercial CMS molecules driving near-term growth.
  3. CMS orders New project orders in CMS grew and will be delivered over this and next financial years.
  4. Concentration CMS revenue is highly concentrated in customers, with top 5 customers at 71% of CMS revenue in Q2FY27.

Original filing on BSE

Neuland Laboratories Limited Q2 FY27 results

As filed: Revenue ₹450 cr (−13% year on year), EBITDA ₹97.6 cr (−37% year on year), PAT ₹51.6 cr (−47% year on year), EBITDA margin 21.7% (−846 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹642 cr (+119% year on year), EBITDA ₹223 cr (+300% year on year), PAT ₹148 cr (+300% year on year), EBITDA margin 34.7% (+1,000 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue fell 17% from last quarter. Share price after the results: +13.5% in 30 days (Nifty 500: −2.0%).
  • Q4 FY26: Revenue ₹776 cr (+137% year on year), EBITDA ₹307 cr (+300% year on year), PAT ₹213 cr (+300% year on year), EBITDA margin 39.6% (+1,000 bps). Score 100 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −0.2% in 30 days (Nifty 500: −0.8%).
  • Q3 FY26: Revenue ₹440 cr (+10% year on year), EBITDA ₹77.1 cr (−10% year on year), PAT ₹40.6 cr (−60% year on year), EBITDA margin 17.5% (−406 bps). Score 44 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin fell 406 bps year on year. Revenue fell 14% from last quarter. Share price after the results: −7.6% in 30 days (Nifty 500: −6.9%).
  • Q2 FY26: Revenue ₹514 cr (+65% year on year), EBITDA ₹155 cr (+150% year on year), PAT ₹97.0 cr (+194% year on year), EBITDA margin 30.2% (+1,000 bps). Score 100 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −5.3% in 28 days (Nifty 500: +1.3%).
  • Q1 FY26: Revenue ₹293 cr (−33% year on year), EBITDA ₹35.0 cr (−72% year on year), PAT ₹14.0 cr (−86% year on year), EBITDA margin 12.0% (−1,000 bps). Score 15 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Other income 44% of PBT. Revenue fell 11% from last quarter. Share price after the results: +1.3% in 29 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹328 cr (−15% year on year), EBITDA ₹51.0 cr (−52% year on year), PAT ₹28.0 cr (−59% year on year), EBITDA margin 15.6% (−1,000 bps). Score 28 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin fell 1000 bps year on year. Revenue fell 18% from last quarter. Share price after the results: +11.2% in 29 days (Nifty 500: +0.5%).
  • Q3 FY25: Revenue ₹398 cr (+1% year on year), EBITDA ₹86.0 cr (−29% year on year), PAT ₹102 cr (−31% year on year), EBITDA margin 21.6% (−918 bps). Score 36 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit before exceptional items growth were below it. EBITDA margin fell 918 bps year on year.

Past price moves after results do not indicate future moves. Not a recommendation.

Neuland Laboratories Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.